Exploiting APC function as a novel cancer therapy

Current Drug Targets

Volumn 15, Issue 1, 2014, Pages 90-102

  Lesko, Alyssa C ^a   Goss, Kathleen H ^b   Prosperi, Jenifer R ^a,c  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APC; Cancer; Targeted therapy; Tumor suppressor

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; CYCLOOXYGENASE 2; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; KARYOPHERIN BETA; PLAKOGLOBIN; TUMOR NECROSIS FACTOR; VASCULAR ENDOTHELIAL CADHERIN; WNT PROTEIN; ACTIN; AMINOGLYCOSIDE; APC PROTEIN; CASEIN KINASE I; CASEIN KINASE II; CELECOXIB; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DASATINIB; ERLOTINIB; MACROLIDE; MUCIN 1; NAVELBINE; NOCODAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PKF 115 584; SULINDAC; SURVIVIN; T CELL FACTOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VINCA ALKALOID;

APOPTOSIS; CANCER THERAPY; CELL CYCLE PARAMETERS; CELL FUNCTION; CELL MIGRATION; CELL POLARITY; COLON POLYPOSIS; DNA REPAIR; DNA REPLICATION; ENZYME ACTIVITY; GENE MUTATION; MICROTUBULE ASSEMBLY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; DNA METHYLATION; GENE SILENCING; HUMAN; NONHUMAN; PROTEIN DEPLETION; PROTEIN FUNCTION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DNA REPAIR; DNA REPLICATION; DRUG RESISTANCE, NEOPLASM; GENES, APC; HUMANS; NEOPLASMS;

EID: 84892978762     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450114666131108155418     Document Type: Review

References (177)

1. Herrera L, Kakati S, Gibas L, Pietrzak E, Sandberg AA. Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 1986; 25(3): 473-6.
2. Tanaka K, Oshimura M, Kikuchi R, et al. Supression of tumorigenicity in human colon cancer cells by introduction of normal chromosome 5 or 18. Nature 1989; 349: 340-42.
3. Leppert M, Burt R, Hughes JP, et al. Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. N Engl J Med 1990; 322: 904-8.
4. Prosperi JR, Lue HH, Goss KH. Dysregulation of the WNT Pathway in Solid Tumors. Targeting the Wnt Pathway in Cancer (Goss and Kahn, eds) 2011: 81-128.
5. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87(2): 159-70.
6. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 18(9): 1967-79.
7. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25(57): 7531-7.
8. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer [published erratum appears in Cell 1994 Apr 8; 77(1): 167]. Cell 1993; 75(5): 1027-38.
9. Nelson S, Nathke IS. Interactions and functions of the adenomatous polyposis coli (APC) protein at a glance. J Cell Sci 2013; 126(Pt 4): 873-7.
10. Prosperi JR, Goss KH. Wnt Pathway-Independent Activities of the APC Tumor Suppressor. Tumor Suppressors (Ed: Susan D Nguyen) 2011.
11. Moser AR, Shoemaker AR, Connelly CS, et al. Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation. Dev Dyn 1995; 203(4): 422-33.
12. Mogensen MM, Tucker JB, Mackie JB, Prescott AR, Nathke IS. The adenomatous polyposis coli protein unambiguously localizes to microtubule plus ends and is involved in establishing parallel arrays of microtubule bundles in highly polarized epithelial cells. J Cell Biol 2002; 157(6): 1041-8.
13. Prosperi JR, Becher KR, Willson TA, et al. The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland. J Cell Physiol 2009; 220(2): 319-31.
14. Lu B, Roegiers F, Jan LY, Jan YN. Adherens junctions inhibit asymmetric division in the Drosophila epithelium. Nature 2001; 409(6819): 522-5.
15. Breitman M, Zilberberg A, Caspi M, Rosin-Arbesfeld R. The armadillo repeat domain of the APC tumor suppressor protein interacts with Striatin family members. Biochim Biophys Acta 2008; 1783(10): 1792-802.
16. Hamada F, Bienz M. The APC tumor suppressor binds to Cterminal binding protein to divert nuclear beta-catenin from TCF. Dev Cell 2004; 7(5): 677-85.
17. Nadauld LD, Phelps R, Moore BC, et al. Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases. J Biol Chem 2006; 281(49): 37828-35.
18. Marshall TW, Lloyd IE, Delalande JM, Nathke I, Rosenblatt J. The tumor suppressor adenomatous polyposis coli controls the direction in which a cell extrudes from an epithelium. Mol Biol Cell 2011; 22(21): 3962-70.
19. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2(6): 442-54.
20. Huang L, Muthuswamy SK. Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Curr Opin Genet Dev 2010; 20(1): 41-50.
21. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28(1-2): 151-66.
22. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13(1): 59-67.
23. Gardiol D, Zacchi A, Petrera F, Stanta G, Banks L. Human discs large and scrib are localized at the same regions in colon mucosa and changes in their expression patterns are correlated with loss of tissue architecture during malignant progression. Int J Cancer 2006; 119(6): 1285-90.
24. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta-catenin. Science 1993; 262(5140): 1731-4.
25. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994; 6(3): 273-81.
26. Rubinfeld B, Souza B, Albert I, Munemitsu S, Polakis P. The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin. Journal of Biological Chemistry 1995; 270(10): 5549-55.
27. Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 1994; 127(6 Pt 2): 2061-9.
28. Wong MH, Hermiston ML, Syder AJ, Gordon JI. Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium. Proc Natl Acad Sci USA 1996; 93(18): 9588-93.
29. Mahmoud NN, Boolbol SK, Bilinski RT, et al. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res 1997; 57(22): 5045-50.
30. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc In vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18(12): 1385-90.
31. Faux MC, Ross JL, Meeker C, et al. Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. J Cell Sci 2004; 117(Pt 3): 427-39.
32. Harris ES, Nelson WJ. Adenomatous polyposis coli regulates endothelial cell migration independent of roles in beta-catenin signaling and cell-cell adhesion. Mol Biol Cell 2010; 21(15): 2611-23.
33. Jamora C, DasGupta R, Kocieniewski P, Fuchs E. Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 2003; 422(6929): 317-22.
34. Odenwald M, Prosperi JR, Goss KH. APC/α-catenin-rich complexes at membrane protrusions are required for mammary tumor cell migration and invasion. BMC Cancer 2013; 13(12).
35. Rosin-Arbesfeld R, Ihrke G, Bienz M. Actin-dependent membrane association of the APC tumour suppressor in polarized mammalian epithelial cells. Embo J 2001; 20(21): 5929-39.
36. Moseley JB, Bartolini F, Okada K, et al. Regulated binding of adenomatous polyposis coli protein to actin. J Biol Chem 2007; 282(17): 12661-8.
37. Okada K, Bartolini F, Deaconescu AM, et al. Adenomatous polyposis coli protein nucleates actin assembly and synergizes with the formin mDia1. J Cell Biol 2010; 189(7): 1087-96.
38. Kawasaki Y, Sato R, Akiyama T. Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol 2003; 5(3): 211-5.
39. Kawasaki Y, Senda T, Ishidate T, et al. Asef, a link between the tumor suppressor APC and G-protein signaling. Science 2000; 289(5482): 1194-7.
40. Kawasaki Y, Sagara M, Shibata Y, et al. Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42. Oncogene 2007; 26(55): 7620-267.
41. Hamann MJ, Lubking CM, Luchini DN, Billadeau DD. Asef2 functions as a Cdc42 exchange factor and is stimulated by the release of an autoinhibitory module from a concealed C-terminal activation element. Mol Cell Biol 2007; 27(4): 1380-93.
42. Watanabe T, Wang S, Noritake J, et al. Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. Dev Cell 2004; 7(6): 871-83.
43. Tirnauer JS. A new cytoskeletal connection for APC: linked to actin through IQGAP. Dev Cell 2004; 7(6): 778-80.
44. Munemitsu S, Souza B, Muller O, et al. The APC gene product associates with microtubules In vivo and promotes their assembly In vitro. Cancer Research 1994; 54(14): 3676-81.
45. Zumbrunn J, Kinoshita K, Hyman AA, Nathke IS. Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation. Curr Biol 2001; 11(1): 44-9.
46. Kita K, Wittmann T, Nathke IS, Waterman-Storer CM. Adenomatous polyposis coli on microtubule plus ends in cell extensions can promote microtubule net growth with or without EB1. Mol Biol Cell 2006; 17(5): 2331-45.
47. Mimori-Kiyosue Y, Shiina N, Tsukita S. The dynamic behavior of the APC-binding protein EB1 on the distal ends of microtubules. Curr Biol 2000; 10(14): 865-8.
48. Askham JM, Moncur P, Markham AF, Morrison EE. Regulation and function of the interaction between the APC tumour suppressor protein and EB1. Oncogene 2000; 19(15): 1950-8.
49. Jimbo T, Kawasaki Y, Koyama R, et al. Identification of a link between the tumour suppressor APC and the kinesin superfamily. Nat Cell Biol 2002; 4(4): 323-7.
50. Wen Y, Eng CH, Schmoranzer J, et al. EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration. Nat Cell Biol 2004; 6(9): 820-30.
51. Jaulin F, Kreitzer G. KIF17 stabilizes microtubules and contributes to epithelial morphogenesis by acting at MT plus ends with EB1 and APC. J Cell Biol 2010; 190(3): 443-60.
52. Dikovskaya D, Li Z, Newton IP, et al. Microtubule assembly by the Apc protein is regulated by importin-beta--RanGTP. J Cell Sci 2010; 123(Pt 5): 736-46.
53. Collin L, Schlessinger K, Hall A. APC nuclear membrane association and microtubule polarity. Biol Cell 2008; 100(4): 243-52.
54. Murawala P, Tripathi MM, Vyas P, Salunke A, Joseph J. Nup358 interacts with APC and plays a role in cell polarization. J Cell Sci 2009; 122(Pt 17): 3113-22.
55. Etienne-Manneville S, Manneville JB, Nicholls S, Ferenczi MA, Hall A. Cdc42 and Par6-PKCzeta regulate the spatially localized association of Dlg1 and APC to control cell polarization. J Cell Biol 2005; 170(6): 895-901.
56. Nathke IS, Adams CL, Polakis P, Sellin JH, Nelson WJ. The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration. Journal of Cell Biology 1996; 134(1): 165-79.
57. Barth AI, Pollack AL, Altschuler Y, Mostov KE, Nelson WJ. NH2-terminal deletion of beta-catenin results in stable colocalization of mutant beta-catenin with adenomatous polyposis coli protein and altered MDCK cell adhesion. J Cell Biol 1997; 136(3): 693-706.
58. Kroboth K, Newton IP, Kita K, et al. Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stability. Mol Biol Cell 2007; 18(3): 910-8.
59. Etienne-Manneville S, Hall A. Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 2003; 421(6924): 753-6.
60. Matsumoto S, Fumoto K, Okamoto T, Kaibuchi K, Kikuchi A. Binding of APC and dishevelled mediates Wnt5a-regulated focal adhesion dynamics in migrating cells. Embo J 2010; 29(7): 1192-204.
61. Ashton GH, Morton JP, Myant K, et al. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell 2010; 19(2): 259-69.
62. Prosperi JR, Khramtsov AI, Khramtsova GF, Goss KH. Apc mutation enhances PyMT-induced mammary tumorigenesis. PLoS One 2011; 6(12): e29339.
63. Olmeda D, Castel S, Vilaro S, Cano A. Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell 2003; 14(7): 2844-60.
64. Trzepacz C, Lowy AM, Kordich JJ, Groden J. Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34. J Biol Chem 1997; 272(35): 21681-4.
65. Bhattacharjee RN, Hamada F, Toyoshima K, Akiyama T. The tumor suppressor gene product APC is hyperphosphorylated during the M phase. Biochem Biophys Res Commun 1996; 220(1): 192-5.
66. Beamish H, de Boer L, Giles N, et al. Cyclin A/cdk2 regulates adenomatous polyposis coli-dependent mitotic spindle anchoring. J Biol Chem 2009; 284(42): 29015-23.
67. Green RA, Wollman R, Kaplan KB. APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment. Mol Biol Cell 2005; 16(10): 4609-22.
68. Zhang J, Ahmad S, Mao Y. BubR1 and APC/EB1 cooperate to maintain metaphase chromosome alignment. J Cell Biol 2007; 178(5): 773-84.
69. Baeg GH, Matsumine A, Kuroda T, et al. The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase. Embo J 1995; 14(22): 5618-25.
70. Carson DJ, Santoro IM, Groden J. Isoforms of the APC tumor suppressor and their ability to inhibit cell growth and tumorigenicity. Oncogene 2004; 23(42): 7144-8.
71. Heinen CD, Goss KH, Cornelius JR, et al. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology 2002; 123: 751-63.
72. Ishidate T, Matsumine A, Toyoshima K, Akiyama T. The APChDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase. Oncogene 2000; 19(3): 365-72.
73. Deka J, Kuhlmann J, Muller O. A domain within the tumor suppressor protein APC shows very similar biochemical properties as the microtubule-associated protein tau. Eur J Biochem 1998; 253(3): 591-7.
74. Qian J, Sarnaik AA, Bonney TM, et al. The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology 2008; 135(1): 152-62.
75. Fodde R, Kuipers J, Rosenberg C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3(4): 433-8.
76. Caldwell CM, Green RA, Kaplan KB. APC mutations lead to cytokinetic failures In vitro and tetraploid genotypes in Min mice. J Cell Biol 2007; 178(7): 1109-20.
77. Dikovskaya D, Schiffmann D, Newton IP, et al. Loss of APC induces polyploidy as a result of a combination of defects in mitosis and apoptosis. J Cell Biol 2007; 176(2): 183-95.
78. Tighe A, Johnson VL, Taylor SS. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J Cell Sci 2004; 117(Pt 26): 6339-53.
79. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multifunctional tumor suppressor gene. J Cell Sci 2007; 120(Pt 19): 3327-35.
80. Zhang F, White RL, Neufeld KL. Cell density and phosphorylation control the subcellular localization of adenomatous polyposis coli protein. Mol Cell Biol 2001; 21(23): 8143-56.
81. Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y. Association and regulation of casein kinase 2 activity by adenomatous polyposis coli protein. Proc Natl Acad Sci USA 2002; 99(9): 5959-64.
82. Narayan S, Jaiswal AS, Balusu R. Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J Biol Chem 2005; 280(8): 6942-9.
83. Jaiswal AS, Narayan S. A novel function of adenomatous polyposis coli (APC) in regulating DNA repair. Cancer Lett 2008; 271(2): 272-80.
84. Wang Y, Azuma Y, Moore D, Osheroff N, Neufeld KL. Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition. Mol Biol Cell 2008; 19(10): 4076-85.
85. Radulescu S, Ridgway RA, Appleton P, et al. Defining the role of APC in the mitotic spindle checkpoint In vivo: APC-deficient cells are resistant to Taxol. Oncogene 2010; 29(49): 6418-27.
86. Draviam VM, Shapiro I, Aldridge B, Sorger PK. Misorientation and reduced stretching of aligned sister kinetochores promote chromosome missegregation in EB1-or APC-depleted cells. Embo J 2006; 25(12): 2814-27.
87. Balusu R, Jaiswal AS, Armas ML, et al. Structure/function analysis of the interaction of adenomatous polyposis coli with DNA polymerase beta and its implications for base excision repair. Biochemistry 2007; 46(49): 13961-74.
88. Jaiswal AS, Balusu R, Armas ML, Kundu CN, Narayan S. Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry 2006; 45(51): 15903-14.
89. Kouzmenko AP, Takeyama K, Kawasaki Y, Akiyama T, Kato S. Truncation mutations abolish chromatin-associated activities of adenomatous polyposis coli. Oncogene 2008; 27(36): 4888-99.
90. Narayan S, Jaiswal AS. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. J Biol Chem 1997; 272(49): 30619-22.
91. Jaiswal AS, Balusu R, Narayan S. 7, 12-Dimethylbenzanthracenedependent transcriptional regulation of adenomatous polyposis coli (APC) gene expression in normal breast epithelial cells is mediated by GC-box binding protein Sp3. Carcinogenesis 2006; 27(2): 252-61.
92. Jaiswal AS, Multani AS, Pathak S, Narayan S. N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol Cancer 2004; 3: 3.
93. Jaiswal AS, Narayan S. Protein synthesis and transcriptional inhibitors control N-methyl-N'-nitro-N-nitrosoguanidine-induced levels of APC mRNA in a p53-dependent manner. International Journal of Oncology 1998; 13(4): 733-40.
94. Browne SJ, MacFarlane M, Cohen GM, Paraskeva C. The adenomatous polyposis coli protein and retinoblastoma protein are cleaved early in apoptosis and are potential substrates for caspases. Cell Death Differ 1998; 5(3): 206-13.
95. Browne SJ, Williams AC, Hague A, Butt AJ, Paraskeva C. Loss of APC protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosis In vitro. Int J Cancer 1994; 59(1): 56-64.
96. Venesio T, Balsamo A, Scordamaglia A, et al. Germline APC mutation on the beta-catenin binding site is associated with a decreased apoptotic level in colorectal adenomas. Mod Pathol 2003; 16(1): 57-65.
97. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996; 93(15): 7950-4.
98. Zhang T, Otevrel T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001; 61(24): 8664-7.
99. Steigerwald K, Behbehani GK, Combs KA, Barton MC, Groden J. The APC tumor suppressor promotes transcription-independent apoptosis In vitro. Mol Cancer Res 2005; 3(2): 78-89.
100. Clarke AR. Studying the consequences of immediate loss of gene function in the intestine: APC. Biochem Soc Trans 2005; 33(Pt 4): 665-6.
101. Zhang L, Ren X, Alt E, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 2010; 464(7291): 1058-61. Epub 2010/03/30.
102. Huang J, Papadopoulos N, McKinley AJ, et al. APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 1996; 93(17): 9049-54.
103. Miyaki M, Konishi M, Kikuchi-Yanoshita R, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 1994; 54(11): 3011-20.
104. Miyoshi K, Shillingford JM, Le Provost F, et al. Activation of beta.-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci USA 2002; 99(1): 219-24
105. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359(6392): 235-7.
106. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000; 97(7): 3352-7.
107. Diergaarde B, van Geloof WL, van Muijen GN, Kok FJ, Kampman E. Dietary factors and the occurrence of truncating APC mutations in sporadic colon carcinomas: a Dutch population-based study. Carcinogenesis 2003; 24(2): 283-90.
108. Fukushima H, Yamamoto H, Itoh F, et al. Frequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability. J Exp Clin Cancer Res 2001; 20(4): 553-9.
109. Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996; 111(2): 307-17.
110. Luchtenborg M, Weijenberg MP, Wark PA, et al. Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 2005; 5: 160.
111. Tsai MH, Yang YC, Chen KH, et al. RER and LOH association with sporadic colorectal cancer in Taiwanese patients. Hepatogastroenterology 2002; 49(45): 672-7.
112. Yashima K, Nakamori S, Murakami Y, et al. Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers. Int J Cancer 1994; 59(1): 43-7.
113. Yu C, Wang J. [Mutation of APC gene in sporadic colorectal tumors]. Zhonghua Zhong Liu Za Zhi 1998; 20(5): 348-50.
114. De Filippo C, Luceri C, Caderni G, et al. Mutations of the APC gene in human sporadic colorectal cancers. Scand J Gastroenterol 2002; 37(9): 1048-53.
115. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992; 1(4): 229-33.
116. Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 1999; 5(9): 1071-5.
117. Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000; 60(16): 4366-71.
118. Lind GE, Thorstensen L, Lovig T, et al. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 2004; 3: 28.
119. Segditsas S, Sieber OM, Rowan A, et al. Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol 2008; 85(3): 201-6.
120. Hiltunen MO, Alhonen L, Koistinaho J, et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer 1997; 70(6): 644-8.
121. Arnold CN, Goel A, Niedzwiecki D, et al. APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther 2004; 3(10): 960-4.
122. Jonsson M, Borg A, Nilbert M, Andersson T. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer 2000; 36(2): 242-8.
123. Ozaki S, Ikeda S, Ishizaki Y, et al. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 2005; 14(6): 1437-43.
124. Abraham SC, Reynolds C, Lee JH, et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 2002; 33(1): 39-46.
125. Wada M, Miller CW, Yokota J, et al. Molecular analysis of the adenomatous polyposis coli gene in sarcomas, hematological malignancies and noncolonic, neoplastic tissues. J Mol Med 1997; 75(2): 139-44.
126. Kashiwaba M, Tamura G, Ishida M. Aberrations of the APC gene in primary breast carcinoma. J Cancer Res Clin Oncol 1994; 120(12): 727-31.
127. Furuuchi K, Tada M, Yamada H, et al. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 2000; 156(6): 1997-2005.
128. Prasad CP, Mirza S, Sharma G, et al. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/betacatenin pathway in invasive ductal carcinoma of breast. Life Sci 2008; 83(9-10): 318-25.
129. Jin Z, Tamura G, Tsuchiya T, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001; 85(1): 69-73.
130. Virmani AK, Rathi A, Sathyanarayana UG, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001; 7(7): 1998-2004.
131. Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003; 106(2): 208-15.
132. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10(18 Pt 1): 6189-93.
133. Van der Auwera I, Van Laere SJ, Van den Bosch SM, et al. Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer 2008; 99(10): 1735-42.
134. Mukherjee N, Bhattacharya N, Alam N, et al. Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance. Cancer Sci 2012; 103(2): 210-20.
135. Lopez-Knowles E, Zardawi SJ, McNeil CM, et al. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2010; 19(1): 301-9.
136. Khramtsov AI, Khramtsova GF, Tretiakova M, et al. Wnt/betacatenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010; 176(6): 2911-20.
137. Phelps RA, Broadbent TJ, Stafforini DM, Jones DA. New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle 2009; 8(16): 2549-56.
138. Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001; 20(27): 3528-32.
139. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62(2): 371-5.
140. Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10(24): 8472-8.
141. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005; 11(11): 4097-106.
142. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64(6): 1975-86.
143. Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002; 160(3): 953-62.
144. Chetty R, Serra S, Salahshor S, et al. Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. Hum Pathol 2006; 37(2): 212-7.
145. Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposisassociated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001; 159(5): 1619-27.
146. Kastritis E, Murray S, Kyriakou F, et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer 2009; 124(1): 103-8.
147. Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol 2006; 37(8): 1042-9.
148. Castiglia D, Bernardini S, Alvino E, et al. Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer 2008; 47(7): 614-24.
149. Korabiowska M, Schlott T, Siems N, et al. Analysis of adenomatous polyposis coli gene expression, APC locusmicrosatellite instability and APC promoter methylation in the progression of melanocytic tumours. Mod Pathol 2004; 17(12): 1539-44.
150. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 2004; 23(30): 5215-26.
151. Prosperi JR, Goss KH. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 2010; 11(9): 1074-88.
152. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA. Suppression of beta-catenin inhibits the neoplastic growth of APCmutant colon cancer cells. Cancer Res 2001; 61(17): 6563-8.
153. Foley PJ, Scheri RP, Smolock CJ, et al. Targeted suppression of beta-catenin blocks intestinal adenoma formation in APC Min mice. J Gastrointest Surg 2008; 12(8): 1452-8.
154. Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5(1): 91-102.
155. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101(34): 12682-7.
156. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005; 24(22): 3619-31.
157. Handeli S, Simon JA. A small-molecule inhibitor of Tcf/betacatenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther 2008; 7(3): 521-9.
158. Grossmann TN, Yeh JT, Bowman BR, et al. Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin. Proc Natl Acad Sci USA 2012; 109(44): 17942-7.
159. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63(3): 728-34.
160. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87(5): 803-9.
161. Inoue K, Fry EA, Taneja P. Recent progress in mouse models for tumor suppressor genes and its implications in human cancer. Clin Med Insights Oncol 2013; 7: 103-22.
162. Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007; 67(19): 9380-8.
163. Itano O, Yang K, Fan K, et al. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis 2009; 30(11): 1923-6.
164. Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol 2011; 25(4-5): 607-22.
165. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006; 94(3): 346-50.
166. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13(1): 11-26.
167. Arenas RB, Fichera A, Mok P, Blanco MC, Michelassi F. Introduction of human adenomatous polyposis coli gene into Min mice via cationic liposomes. Surgery 1996; 120(4): 712-7; discussion 7-8.
168. Groden J, Joslyn G, Samowitz W, et al. Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Research 1995; 55(7): 1531-9.
169. Zilberberg A, Lahav L, Rosin-Arbesfeld R. Restoration of APC gene function in colorectal cancer cells by aminoglycoside-and macrolide-induced read-through of premature termination codons. Gut 2010; 59(4): 496-507.
170. Hiscox S, Nicholson RI. Src inhibitors in breast cancer therapy. Expert Opin Ther Targets 2008; 12(6): 757-67.
171. Dunn KB, Heffler M, Golubovskaya VM. Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2010; 10(10): 722-34.
172. Kundu CN, Balusu R, Jaiswal AS, Narayan S. Adenomatous polyposis coli-mediated hypersensitivity of mouse embryonic fibroblast cell lines to methylmethane sulfonate treatment: implication of base excision repair pathways. Carcinogenesis 2007; 28(10): 2089-95.
173. Kim JC, Roh SA, Cho DH, et al. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. Anticancer Res 2009; 29(8): 3115-23.
174. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007; 59(11): 696-9.
175. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41(Database issue): D955-61.
176. Zatelli MC, Luchin A, Tagliati F, et al. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 2007; 14(4): 1029-38.
177. Klotz DM, Nelson SA, Kroboth K, et al. The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively. J Cell Sci 2012; 125(Pt 4): 887-95.